Vertex Pharmaceuticals (VRTX) Other Accumulated Expenses (2009 - 2026)

Vertex Pharmaceuticals' Other Accumulated Expenses history runs 18 years deep, the most recent figure standing at $407.1 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 5.36% year-over-year to $407.1 million; the TTM figure through Mar 2026 stood at $407.1 million (up 5.36% YoY), while the FY2025 annual figure was $428.3 million, up 17.99% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $407.1 million, down from $428.3 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $648.6 million in Q1 2024, with the low at $218.0 million in Q3 2022.
• The 5-year median for Other Accumulated Expenses is $377.0 million (2023), against an average of $376.6 million.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses surged 72.04% in 2024, then sank 40.43% in 2025.
• Vertex Pharmaceuticals' Other Accumulated Expenses stood at $311.5 million in 2022, then soared by 69.25% to $527.2 million in 2023, then slumped by 31.15% to $363.0 million in 2024, then advanced by 17.99% to $428.3 million in 2025, then retreated by 4.95% to $407.1 million in 2026.
• Business Quant data shows VRTX's Other Accumulated Expenses at $407.1 million in Q1 2026, $428.3 million in Q4 2025, and $441.5 million in Q3 2025.